<DOC>
	<DOCNO>NCT01139359</DOCNO>
	<brief_summary>This study Phase I trial Darinaparsin combination CHOP treatment lymphoma . Eligible patient previous anti-cancer treatment eligible receive CHOP alone .</brief_summary>
	<brief_title>Safety Study Darinaparsin Combination With Cyclophosphamide , Doxorubicin , Vincristine , Prednisone ( CHOP ) Treat Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Patients histological cytological confirmation lymphoma previously untreated schedule receive CHOP alone . Since objective study assessment safety , eligible subject may type lymphoma ( Hodgkin 's nonHodgkin 's , Tcell Bcell ) , long schedule therapy CHOP alone . Men woman ≥18 year age . ECOG performance score ≤2 Life expectancy ≥12 week . Adequate bone marrow , liver renal function assess follow laboratory requirement , conduct &lt; 2 week prior first dose study drug : Creatinine ≤1.5 × upper limit normal ( ULN ) OR calculate creatinine clearance ≥60 cc/min Total bilirubin ≤2 × ULN Alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≤3 × ULN Granulocytes peripheral blood ≥1 × 109/L , hemoglobin ≥10 g/dL , platelet ≥50,000 /µL Adequate vascular access repeat blood sampling . Men woman childbearing potential must agree use effective contraception Screening 30 day last dose study drug . Written inform consent compliance ZIOPHARM policy Human Investigation Review Committee ( IEC/IRB ) jurisdiction site . Arsenic allergy . New York Heart Association ( NYHA ) functional class ≥3 myocardial infarction ( see Appendix 3 ) within 6 month . Myocardial dysfunction define scintigraphically ( MUGA [ multiple gate acquisition scan ] , myocardial scintigram ) ultrasounddetermined left ventricular ejection fraction ( LVEF ) &lt; 50 % . Uncontrolled cardiac arrhythmia asymptomatic atrial fibrillation ; QTc ≥450 msec ; ≥Grade 2 atrioventricular ( AV ) block leave bundle branch block ( LBBB ) ; document history prolong QTc . Pregnant and/or lactate woman . Uncontrolled systemic infection ( documented microbiological study ) . Metastatic brain meningeal tumor . Patients seizure disorder require medication ( anti branch block ( LBBB ) ; document history prolong QTc . History confusion dementia neurological condition could mask potential adverse response Study Drug , may include transient ischemic attack , Parkinson 's disease , thrombotic hemorrhagic stroke , Alzheimer 's , neurological disorder . Anticancer chemotherapy immunotherapy indication . Radiotherapy study within 3 week Study entry . Major surgery within 4 week start Study Drug dose . Investigational drug therapy outside trial . History invasive second primary malignancy diagnose within previous 3 year except Stage I endometrial/cervical carcinoma prostate carcinoma treat surgically , nonmelanoma skin cancer . Substance abuse , medical , psychological , social condition may interfere patient 's participation study evaluation Study result . Any condition unstable could jeopardize safety patient his/her compliance Study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Darinaparsin</keyword>
	<keyword>CHOP</keyword>
	<keyword>Frontline</keyword>
	<keyword>PTCL</keyword>
	<keyword>B-cell</keyword>
</DOC>